skip to Main Content

First-in-Class, Oral Agent Gets Orphan Drug Status for Pancreatic Cancer

First-in-Class, Oral Agent Gets Orphan Drug Status for Pancreatic Cancer
The Food and Drug Administration (FDA) has granted orphan drug designation to Mesupron (RedHill Biopharma) for the adjuvant treatment of pancreatic cancer.

Mesupron is a first-in-class, orally-administered protease inhibitor; high levels of certain proteases have been associated with poor prognosis for various solid tumor cancers. The drug represents a non-cytotoxic approach to cancer therapy with several potential mechanism of action to inhibit tumor invasion and metastasis. Read more . . .


Back To Top